Administration of LHRH agonist as an adjuvant endocrine therapy for breast cancer is a risk factor of ovarian function recovery after switching from tamoxifen to aromatase inhibitor

Background: Aromatase inhibitor (AI) is thought to be used with caution, when amenorrhea is induced in chemotherapy. But ovarian function recovery (OFR) is also observed in switching from tamoxifen to AI without chemotherapy. Considering the effect of AI, the identical caution is required. This retrospective study assesses the patients-related and therapy-related factors associated with OFR.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: POSTERS A: Systemic Treatment Source Type: research